VIR
HEALTHCAREVir Biotechnology Inc
$10.29+0.28 (+2.80%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VIR Today?
No stock-specific AI insight has been generated for VIR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.16$11.66
$10.29
Fundamentals
Market Cap$1.7B
P/E Ratio—
EPS$-3.16
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding161.2M
VIR News
20 articles- Vir Biotechnology Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial ResultsBioSpace·May 7, 2026
- Vir Biotechnology, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Vir (VIR) Q1 2026 Earnings Call TranscriptMotley Fool·May 6, 2026
- Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare ConferenceYahoo Finance·May 5, 2026
- Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue EstimatesYahoo Finance·May 4, 2026
- Why Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii ArbitrationYahoo Finance·Apr 29, 2026
- Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?Yahoo Finance·Apr 26, 2026
- Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial ResultsYahoo Finance·Apr 23, 2026
- Vir Biotechnology (VIR) Posts 80.98% Year-To-Date GrowthYahoo Finance·Apr 22, 2026
- Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer?Yahoo Finance·Apr 20, 2026
- Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?Yahoo Finance·Apr 20, 2026
- Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate CancerYahoo Finance·Apr 16, 2026
- A Look At Vir Biotechnology (VIR) Valuation After New VIR-5500 Prostate Cancer Trial MilestoneYahoo Finance·Apr 14, 2026
- Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate CancerYahoo Finance·Apr 13, 2026
- Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000The Motley Fool·Apr 12, 2026
- Vir Biotechnology (VIR) Leading with Its BiTEs TherapyYahoo Finance·Apr 10, 2026
- Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In FocusYahoo Finance·Feb 28, 2026
- Vir Biotechnology to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 26, 2026
- TheStreet Pro: Four Stocks that Will Win Despite “Irrational Panic” over AIYahoo Finance·Feb 26, 2026
All 20 articles loaded
Price Data
Open$10.09
Previous Close$10.01
Day High$10.31
Day Low$9.99
52 Week High$11.66
52 Week Low$4.16
52-Week Range
$4.16$11.66
$10.29
Fundamentals
Market Cap$1.7B
P/E Ratio—
EPS$-3.16
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding161.2M
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—